Analyst consensus and tracked brokerage price targets for Amarin Corporation (NASDAQ: AMRN) place the average twelve-month target around $12.00 per share. Depending on individual financial institutions and ongoing updates following quarterly earnings reports, projections vary slightly based on the company's operational turnaround, commercialization of Vascepa in global markets, and cost-reduction strategies. Investors should check real-time financial tracking platforms for the latest adjustments by healthcare equity research analysts.